Using a new balloon technique to treat atrial fibrillation
Official title: Pulmonary Vein Isolation With the Single Shot Endoscopic Ultra-Compliant Pulsed Field Ablation Balloon for the Treatment of Atrial Fibrillation
Run by CardioFocus · NCT06828939 · Data updated 2026-11-12
This study is testing a new balloon technique to see if it can safely and effectively treat people with a type of irregular heartbeat called atrial fibrillation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | CardioFocus Industry-sponsored |
| Locations | 1 site (Prague, Czech Republic) |
| Status | Recruiting |
| Started | December 12, 2024 |
| Main results expected | March 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 3, 2026 |
| Trial ID | NCT06828939 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with recurrent symptomatic paroxysmal atrial fibrillation who have not previously undergone catheter ablation.
✕Probably not a fit
Patients who are in overall good health and do not meet the criteria for atrial fibrillation treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and effectiveness of the CardioFocus OptiShot Pulsed Field Ablation System for catheter ablation in patients with symptomatic paroxysmal atrial fibrillation. It is a prospective, single-arm First-in-Human study that includes patients who are undergoing their first pulmonary vein isolation procedure. Participants will be monitored for one year following the initial ablation to assess outcomes and safety. The study aims to provide insights into a novel ablation technique that may improve treatment for this condition.
Why it matters
Potential benefit: If successful, this approach could offer a safer and more effective treatment option for patients with atrial fibrillation.
How similar studies have gone: While this approach is novel, similar studies have shown promise in the use of pulsed field ablation techniques for treating atrial fibrillation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recurrent symptomatic PAF with at least one documented episode * Failure or intolerance of at least one AAD * Age 18-75 years * Patient is indicated for an ablation procedure according to society guidelines or study site practice * Patient is willing and able to give informed consent/participate in baseline and follow-up assessments for the duration of the study Exclusion Criteria: * overall good health as established by multiple criteria
Where it's running
-
Na Homolce Hospital
Prague, Czech Republic, Czechia Recruiting
Study contacts
- Study coordinator: Vikramaditya Mediratta, MS
- Email: vmediratta@cardiofocus.com
- Phone: 714-717-2376
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Biofeedback helps people with paroxysmal atrial fibrillation stay active
This study tests a biofeedback approach using a smartwatch to monitor AF and activity and sends personalized nudges to see if it helps people with paroxysmal AF be more physically active.
-
Progressive Resistance Training First to Help AF and HFpEF Patients Feel Better
This trial tests whether starting with progressive resistance training before aerobic exercise can improve exercise capacity and quality of life in people aged 60 and older who have atrial fibrillation and HFpEF.
-
Digital MediYoga for quality of life and heart measures in paroxysmal atrial fibrillation
This trial will test whether a 12-week, app-delivered MediYoga program can improve disease-specific quality of life and reduce blood pressure and heart rate in adults with paroxysmal atrial fibrillation.
-
Pulsed-field pulmonary vein isolation with optional radiofrequency nerve-targeting for paroxysmal atrial fibrillation
This trial tests whether adding selective radiofrequency ablation of a parasympathetic ganglion to pulsed-field pulmonary vein isolation helps adults with paroxysmal atrial fibrillation have fewer recurrences and fewer bradyarrhythmic events.
-
nano-second pulsed field (nsPFA) catheter ablation for paroxysmal atrial fibrillation using the CellFX system
The study will try the CellFX nano-second pulsed field catheter to treat adults with recurrent, drug-resistant paroxysmal atrial fibrillation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.